What is Kailera Therapeutics, Inc. Common Stock?
operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.43B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 0 | 520,421,876 shares $326.8M |
| 9-12months | 0 | 0 |